Pages that link to "Q33403059"

The following pages link to Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. (Q33403059):

Displaying 23 items.

• Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends (Q30235355) (← links)
• Established and emerging targeted therapies in the myelodysplastic syndromes (Q30245476) (← links)
• Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide (Q33433453) (← links)
• Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis (Q33436627) (← links)
• Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge (Q33678636) (← links)
• Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy (Q33914183) (← links)
• Current therapy of myelodysplastic syndromes (Q34013796) (← links)
• Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes (Q34783754) (← links)
• Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response (Q35638905) (← links)
• Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion (Q37075929) (← links)
• Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. (Q37449333) (← links)
• Where Does Lenalidomide Fit in Non-del(5q) MDS? (Q38546273) (← links)
• Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis (Q38595266) (← links)
• Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies (Q38655060) (← links)
• Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications (Q38758162) (← links)
• Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management (Q40420210) (← links)
• Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling (Q48252834) (← links)
• Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial (Q50095638) (← links)
• Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. (Q50280245) (← links)
• The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. (Q52777531) (← links)
• A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). (Q53339839) (← links)
• Myelodysplastic syndromes (Q87492688) (← links)
• Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil (Q90055646) (← links)